ORMPOramed Pharmaceuticals, Inc

Oramed’s stock price is likely driven more by clinical and balance-sheet developments than by traditional revenue growth, because the company currently reports little to no operating revenue.

The very low price-to-earnings ratio and high earnings yield appear to be influenced by non-operating or investment-related net income rather than recurring product sales, so investors may treat those figures cautiously.

The stock can move sharply on announcements related to ORMD-0801, oral GLP-1 development, regulatory feedback, trial results, dividends, buybacks, and strategic investments.

The recent Alpha Tau Medical investment may also affect sentiment because it creates exposure to another biotechnology platform and signals active capital allocation by management.

Broader biotech market risk appetite, interest rates, diabetes-drug enthusiasm, and penny-stock momentum can also influence valuation.

With a beta above 1 and trading near the lower portion of its 52-week range, the shares may be sensitive to both company-specific news and broader speculative small-cap trends.

Recent news reported that Alpha Tau Medical closed a registered direct offering in which an affiliate of Oramed Pharmaceuticals purchased 14,110,121 ordinary shares at $2.612 per share.

The transaction generated about $36.9 million in gross proceeds for Alpha Tau before expenses and closed on April 28, 2025.

Alpha Tau plans to use the proceeds for general corporate purposes, including R&D, manufacturing expansion, and potential commercialization.

Oramed and Alpha Tau also entered into a three-year strategic services agreement under which an Oramed affiliate will provide investor relations and public relations support in exchange for payments and warrants.

Oramed’s CEO Nadav Kidron expressed confidence in Alpha Tau’s Alpha DaRT technology and management team.

Another recent article highlighted Oramed as a financially strong penny stock, citing its debt-free profile, reported net income, cash dividend from surplus capital, and share buybacks, while also noting that it remains largely pre-revenue.

Oramed is affected by several broad market trends in biotechnology, diabetes treatment, and small-cap investing.

Demand for diabetes and metabolic disease treatments remains strong, especially as GLP-1 therapies have reshaped investor expectations for the sector.

Patients, physicians, and payers continue to value therapies that improve adherence, reduce injection burden, and simplify chronic disease management.

At the same time, investors have become more selective with clinical-stage biotechnology companies because higher interest rates and funding uncertainty can pressure companies without recurring revenue.

Small-cap and penny-stock biotech names can rally quickly when risk appetite improves, but they can also decline sharply when markets favor profitable large-cap companies.

Strategic investment activity, licensing deals, and balance-sheet strength are increasingly important differentiators for smaller pharmaceutical companies that need to survive long development timelines.